| Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to … M Westwood, S Lang, N Armstrong, S van Turenhout, J Cubiella, L Stirk, ... BMC medicine 15 (1), 1-17, 2017 | 117 | 2017 |
| Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost … M Westwood, IC Ramos, S Lang, M Luyendijk, R Zaim, L Stirk, M Al, ... Health technology assessment (Winchester, England) 21 (33), 1, 2017 | 82 | 2017 |
| Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations MS Holleman, MJ Al, R Zaim, HJM Groen, CA Uyl-de Groot The European Journal of Health Economics 21, 153-164, 2020 | 38 | 2020 |
| Real‐world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis R Maan, R Zaim, AJ van der Meer, JJ Feld, H Wedemeyer, JF Dufour, ... Journal of gastroenterology and hepatology 31 (11), 1851-1859, 2016 | 9 | 2016 |
| Value assessment methods and pricing recommendations for potential cures: a technical brief R Chapman, V Kumar, S Samur, R Zaim, C Segel, S Pearson Institute for Clinical and Economic Review. August 6, 2019 | 8 | 2019 |
| Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States R Zaim, K Redekop, CA Uyl-de Groot Journal of Cancer Policy 33, 100346, 2022 | 6 | 2022 |
| Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer R Zaim, K Redekop, CA Uyl-de Groot Translational Oncology 20, 101418, 2022 | 5 | 2022 |
| Nivolumab (Opdivo) bij Gevorderd Plaveiselcelcarcinoom van de Long CA Uyl-de Groot, M Al, R Zaim Instituut Beleid & Management Gezondheidszorg, 2015 | 5 | 2015 |
| PCN202 How Should VALUE be Attributed to the Constituent Parts of Combination Immunotherapy in NON-SMALL Cell LUNG Cancer? R Zaim, K Redekop, C Uyl-De Groot Value in Health 23, S458-S459, 2020 | 2 | 2020 |
| 'DE NOVO'Quantification of Genotype-Directed Therapy with Afatinib in Metastatic Lung Cancer R Zaim, L Tran, HJM Groen, CA Uyl-de Groot Value in Health 17 (7), A641, 2014 | 2 | 2014 |
| Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer R Zaim, WK Redekop, CA Uyl-de Groot Frontiers in Oncology 13, 1027659, 2023 | 1 | 2023 |
| Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer R Zaim, K Redekop, CA Uyl-de Groot Journal of Cancer Policy 35, 100382, 2023 | 1 | 2023 |
| Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis R Maan, R Zaim, A van der Meer, J Feld, H Wedemeyer, J Dufour, ... Value in Health 18 (7), A624, 2015 | 1 | 2015 |
| Toward responsible artificial intelligence in health: regulatory structures and power dynamics of the big tech industry in the United States R Zaim, JA Shaw Policy Studies, 1-13, 2024 | | 2024 |
| HTA95 Building a Lifecycle Ethics Framework for the Assessment of Artificial Intelligence Technologies in Health: A Scoping Review of Reviews R Zaim, JA Shaw Value in Health 26 (6), S276, 2023 | | 2023 |
| Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment R Zaim, WK Redekop, CA Uyl-de Groot Frontiers in Health Services 3, 1034256, 2023 | | 2023 |
| Ravulizumab for paroxysmal nocturnal haemoglobinuria: A Single Technology Assessment Riemsma R, Corro Ramos I, Zaim R, Westwood M, Chalker A, Armstrong N, Ahmadu ... https://www.nice.org.uk/guidance/ta698, 2020 | | 2020 |
| Burosumab for treating X-linked hypophosphataemia: A Highly Specialised Technology Evaluation Riemsma R, Corro Ramos I, Büyükkaramikli N, Swift S, Armstrong N, Zaim R, De ... https://www.nice.org.uk/guidance/hst8, 2018 | | 2018 |
| Gefitinib, Erlotinib or Afatinib for EGFR Mutated NSCLC patients? A Meta-Analysis and Indirect Comparison on the Efficacy of First-Line Tyrosine Kinase Inhibitors MS Holleman, R Zaim, CA Uyl-De Groot Value in Health 19 (7), A714, 2016 | | 2016 |
| Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations MS Holleman, R Zaim, CA Uyl-De Groot Value in Health 19 (7), A740-A741, 2016 | | 2016 |
